LEUVEN, Belgium, April 13, 2012 /PRNewswire/ --
ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it has received a transparency declaration from OppenheimerFunds Inc. in accordance with the Belgian Law of 2 May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.
ThromboGenics NV has received a transparency notification from OppenheimerFunds Inc., having its registered office at S.Tucson Way 6803, Centennial, Colorado US, indicating that, following the acquisition of shares, its participation in the company exceeds the 3% threshold. Following the private placement of 29 March 2012, ThromboGenics has now 35.691.432 shares outstanding. As a consequence of this capital increase 2 shareholders have passed a threshold of respectively 10% ( L.T.Clay) and 5% (Baker Brothers) as they did not participate in the recent capital increase.
As per 13 April 2012, based on the transparency notifications received, ThromboGenics NV has been informed of the following major shareholdings:
Shareholder Number of shares % of outstanding shares Landon T Clay 2.576.448 7,21 Biggar Ltd 2.012.105 5,64 Baker Brothers 1.619.488 4,54 OppenheimerFunds Inc. 1.236.688 3,46 Clay Mathematics 1.099.247 3,07About ThromboGenics ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA will be re-submitted in the U.S. by April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions. In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vireoretinal indications. ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer which has been partnered with Roche.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV